Michael N.
- Country
- Germany
- Department
- Hämatologie und Onkologie
Research Overview
Data & Insights
Has run more than one trial at 7 of 96 partner sites.
Specializations
Hematologic Oncology
This investigator specializes in treating Multiple Myeloma and Chronic Lymphocytic Leukemia, with particular emphasis on innovative therapeutic approaches for blood cancers.
- Multiple Myeloma Treatment
- High-Risk CLL Management
- Novel Combination Therapies
The investigator focuses on developing treatment strategies for transplant-ineligible patients and those with high-risk genetic profiles.
Targeted Therapies
The investigator works with novel therapeutic agents including daratumumab, acalabrutinib, obinutuzumab, and venetoclax in blood cancer treatment.
- Monoclonal Antibody Therapy
- BTK Inhibition
- Combination Treatment Approaches
Special attention is given to developing personalized treatment strategies based on genetic risk factors.
Genetic Risk Assessment
The investigator specializes in treating patients with specific genetic markers including 17p-deletion, TP53-mutation, and complex karyotype presentations.
- High-Risk Patient Treatment
- Genetic Profiling
- Risk-Adapted Therapy
Focus is placed on developing treatment strategies for patients with challenging genetic profiles in blood cancers.
Related Investigators
Researchers in similar fields or departments
Want to know more about this investigator?
We can share extended profile information and contact details.
Is something out of date?
Tell us what needs correcting and we'll update this profile.